Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;17(5):6301-6310.
doi: 10.3892/mmr.2018.8713. Epub 2018 Mar 9.

MicroRNA-214-5p/TGF-β/Smad2 signaling alters adipogenic differentiation of bone marrow stem cells in postmenopausal osteoporosis

Jiang Qiu #  1 , Gang Huang #  1 , Ning Na  2 , Lizhong Chen  1
Affiliations

MicroRNA-214-5p/TGF-β/Smad2 signaling alters adipogenic differentiation of bone marrow stem cells in postmenopausal osteoporosis

Jiang Qiu et al. Mol Med Rep. 2018 May.

Abstract

Postmenopausal osteoporosis (OPM) is a common type of osteoporosis in females. It is a systemic, chronic bone disease that presents as microstructure degradation of osseous tissue, decreased bone mineral density and increased osteopsathyrosis caused by hypoovarianism and reduced estrogen levels in the body following menopause. In the present study, the role of microRNA (miR)‑214‑5p in the regulation of the expression of bone marrow stem cells (BMSCs) was investigated, and its molecular mechanism of osteogenic induction in vitro was assessed. When dexamethasone‑induced adipogenic differentiation was performed, miR‑214‑5p expression was increased compared with the control group, as determined by RT‑qPCR. Furthermore, oil red O staining, RT‑qPCR and western blot analysis demonstrated that overexpression of miR‑214‑5p promoted adipogenic differentiation, inhibited alkaline phosphatase (ALP), runt‑related transcription factor 2 (Runx2), osteocalcin (OC) and collagen α‑1 (I) chain (COL1A1) mRNA expression, and suppressed transforming growth factor (TGF)‑β, phosphorylated (p)‑Smad2 and collagen type IV α1 chain (COL4A1) protein expression in BMSCs. Additionally, downregulation of miR‑214‑5p increased the ALP, Runx2, OC and COL1 mRNA expression and increased TGF‑β, Smad2 and COL4A1 protein expression in BMSCs. Furthermore, a TGF‑β inhibitor was employed to inhibit TGF‑β expression in BMSCs following miR‑214‑5p downregulation, which led to reduced Smad2, TGF‑β and COL4A1 protein expression, and ALP, Runx2, OC and COL1 mRNA expression was also reduced, compared with the miR‑214‑5p downregulation only group. It was demonstrated that miR‑214‑5p may weaken osteogenic differentiation of BMSCs through regulating COL4A1. In conclusion, the results of the present study indicated that miR‑214‑5p may promote the adipogenic differentiation of BMSCs through regulation of the TGF‑β/Smad2/COL4A1 signaling pathway, and potentially may be used to develop a novel drug for postmenopausal osteoporosis.

Keywords: microRNA-214-5p; adipogenic differentiation; bone marrow stem cells; transforming growth factor-β; Smad2.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Expression of miR-214-5p in dexamethasone-induced adipogenic differentiation of human bone marrow stem cells. (A) mRNA expression of miR-214-5p was determined by reverse transcription-quantitative polymerase chain reaction. (B) Successful adipogenic differentiation was determined using oil red O staining following dexamethasone treatment. Magnification, ×100. ##P<0.01 vs. control group. miR, microRNA.
Figure 2.
Figure 2.
Adipogenic differentiation was measured by oil red O staining following miR-214-5p downregulation/overexpression in dexamethasone-treated cells. (A) Overexpression of miR-214-5p induced adipogenic differentiation in HBMSCs. (B) miR-214-5p downregulation inhibited adipogenic differentiation in HBMSCs. Magnification, ×100. miR, microRNA; HBMSCs, human bone marrow stem cells; negative, negative control transfection group; miR-214-5p group, overexpression of miR-214-5p group; anti-miR-214-5p group, miR-214-5p downregulation group.
Figure 3.
Figure 3.
Overexpression of miR-214-5p affected ALP, Runx2, OC and COL1A1 mRNA expression. (A) RT-qPCR was initially performed to confirm successful overexpression of miR-214-5p following transfection. RT-qPCR was subsequently performed to determine the effect of miR-214-5p overexpression on (B) ALP, (C) Runx2, (D) OC and (E) COL1 mRNA expression in human bone marrow stem cells. ##P<0.01 vs. negative control group. miR, microRNA; ALP, alkaline phosphatase; Runx2, runt-related transcription factor 2; OC, osteocalcin; COL1A1, collagen type IV α1 chain; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; negative, negative control transfection group; miR-214-5p group, overexpression of miR-214-5p group.
Figure 4.
Figure 4.
Downregulation of miR-214-5p affected ALP, Runx2, OC and COL1A1 mRNA expression. (A) RT-qPCR was initially performed to confirm successful downregulation of miR-214-5p following transfection. RT-qPCR was subsequently performed to determine the effect of anti-miR-214-5p on (B) ALP, (C) Runx2, (D) OC and (E) COL1 mRNA expression in human bone marrow stem cells. ##P<0.01 vs. negative control group. miR, microRNA; ALP, alkaline phosphatase; Runx2, runt-related transcription factor 2; OC, osteocalcin; COL1A1, collagen type IV α1 chain; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; negative, negative control transfection group; anti-miR-214-5p group, miR-214-5p downregulation group.
Figure 5.
Figure 5.
Overexpression of miR-214-5p affected the mRNA expression of PPARγ, CEBPα and adiponectin. Reverse transcription-quantitative polymerase chain reaction demonstrated that miR-214-5p overexpression increased the mRNA levels of (A) PPARγ, (B) CEBPα and (C) adiponectin in human bone marrow stem cells. ##P<0.01 vs. negative control group. miR, microRNA; PPARγ, peroxisome proliferator-activated receptor γ; CEBPα, CCAAT/enhancer-binding protein α; negative, negative control transfection group; miR-214-5p group, overexpression of miR-214-5p group.
Figure 6.
Figure 6.
Downregulation of miR-214-5p affected the mRNA expression of PPARγ, CEBPα and adiponectin. Reverse transcription-quantitative polymerase chain reaction demonstrated that miR-214-5p downregulation reduced the levels of (A) PPARγ, (B) CEBPα and (C) adiponectin in human bone marrow stem cells. ##P<0.01 vs. negative control group. miR, microRNA; PPARγ, peroxisome proliferator-activated receptor γ; CEBPα, CCAAT/enhancer-binding protein α; negative, negative control transfection group; anti-miR-214-5p group, miR-214-5p downregulation group.
Figure 7.
Figure 7.
Overexpression of miR-214-5p suppressed COL4A1, TGF-β and p-Smad2 protein levels. (A) Western blot analysis demonstrated that miR-214-5p overexpression reduced the protein levels of COL4A1, TGF-β and p-Smad2. Densitometric analysis of western blotting results was performed to quantify the protein expression of (B) COL4A1, (C) TGF-β and (D) p-Smad2 following overexpression of miR-214-5p in human bone marrow stem cells. ##P<0.01 vs. negative control group. miR, microRNA; COL4A1, collagen type IV α1 chain; TGF-β, transforming growth factor-β; p-Smad2, phosphorylated-Smad2; negative, negative control transfection group; miR-214-5p group, overexpression of miR-214-5p group.
Figure 8.
Figure 8.
Downregulation of miR-214-5p enhanced the protein expression of COL4A1, TGF-β and p-Smad2. (A) Western blot analysis demonstrated that miR-214-5p downregulation increased the protein levels of COL4A1, TGF-β and p-Smad2. Densitometric analysis of western blotting results was performed to quantify the protein expression of (B) COL4A1, (C) TGF-β and (D) p-Smad2 following downregulation of miR-214-5p in human bone marrow stem cells. ##P<0.01 vs. negative control group. miR, microRNA; COL4A1, collagen type IV α1 chain; TGF-β, transforming growth factor-β; p-Smad2, phosphorylated-Smad2; negative, negative control transfection group; anti-miR-214-5p group, miR-214-5p downregulation group.
Figure 9.
Figure 9.
TGF-β inhibitor reversed the effects of miR-214-5p downregulation on the protein expression of COL4A1, TGF-β and p-Smad2. (A) Western blot analysis demonstrated that TGF-β inhibitor reversed anti-miR-214-5p-induced increases in the protein expression of COL4A1, TGF-β and p-Smad2. Densitometric analysis of western blotting results was performed to quantify the protein expression of (B) COL4A1, (C) TGF-β and (D) p-Smad2 following downregulation of miR-214-5p with or without TGF-β inhibitor treatment in human bone marrow stem cells. (E) Following miR-214-5p downregulation with or without TGF-β inhibitor treatment, adipogenic differentiation was assessed using oil red O staining. Magnification, ×100. ##P<0.01 vs. negative control group; **P<0.01 vs. anti-miR-214-5p group. TGF-β, transforming growth factor-β; miR, microRNA; COL4A1, collagen type IV α1 chain; p-Smad2, phosphorylated-Smad2; negative, negative control transfection group; anti-miR-214-5p group, miR-214-5p downregulation group; TGF-β inhibitor group, miR-214-5p downregulation+TGF-β inhibitor group.
Figure 10.
Figure 10.
TGF-β inhibitor reversed the effects of miR-214-5p downregulation on the mRNA expression of ALP, Runx2, OC and COL1. Reverse transcription-quantitative polymerase chain reaction demonstrated that TGF-β inhibitor reversed the anti-miR-214-5p-induced increases in the mRNA expression of (A) ALP, (B) Runx2, (C) OC and (D) COL1 in human bone marrow stem cells. ##P<0.01 vs. negative control group; **P<0.01 vs. anti-miR-214-5p group. TGF-β, transforming growth factor-β; miR, microRNA; ALP, alkaline phosphatase; Runx2, runt-related transcription factor 2; OC, osteocalcin; COL1A1, collagen type IV α1 chain; negative, negative control transfection group; anti-miR-214-5p group, miR-214-5p downregulation group; TGF-β inhibitor group, miR-214-5p downregulation+TGF-β inhibitor group.
Figure 11.
Figure 11.
TGF-β inhibitor reversed the effects of miR-214-5p downregulation on the mRNA expression of PPARγ, CEBPα and adiponectin. Reverse transcription-quantitative polymerase chain reaction demonstrated that TGF-β inhibitor reversed the anti-miR-214-5p-induced reduction in the mRNA expression of (A) PPARγ, (B) CEBPα and (C) adiponectin in human bone marrow stem cells. ##P<0.01 vs. negative control group; **P<0.01 vs. anti-miR-214-5p group. TGF-β, transforming growth factor-β; miR, microRNA; PPARγ, peroxisome proliferator-activated receptor γ; CEBPα, CCAAT/enhancer-binding protein α; negative, negative control transfection group; anti-miR-214-5p group, miR-214-5p downregulation group; TGF-β inhibitor group, miR-214-5p downregulation + TGF-β inhibitor group.
See this image and copyright information in PMC

References

    1. Pawlowski JW, Martin BR, McCabe GP, McCabe L, Jackson GS, Peacock M, Barnes S, Weaver CM. Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: A randomized crossover trial. Am J Clin Nutr. 2015;102:695–703. doi: 10.3945/ajcn.114.093906. - DOI - PMC - PubMed
    1. Pfeifer M, Kohlwey L, Begerow B, Minne HW. Effects of two newly developed spinal orthoses on trunk muscle strength, posture, and quality-of-life in women with postmenopausal osteoporosis: A randomized trial. Am J Phys Med Rehabil. 2011;90:805–815. doi: 10.1097/PHM.0b013e31821f6df3. - DOI - PubMed
    1. Kessous R, Weintraub AY, Mattan Y, Dresner-Pollak R, Brezis M, Liebergall M, Kandel L. Improving compliance to osteoporosis workup and treatment in postmenopausal patients after a distal radius fracture. Taiwan J Obstet Gynecol. 2014;53:206–209. doi: 10.1016/j.tjog.2014.04.015. - DOI - PubMed
    1. Itabashi A, Yoh K, Chines AA, Miki T, Takada M, Sato H, Gorai I, Sugimoto T, Mizunuma H, Ochi H, et al. Bridging analysis of the efficacy and safety of bazedoxifene in Japanese and global populations of postmenopausal women with osteoporosis. J Bone Miner Metab. 2015;33:61–72. doi: 10.1007/s00774-013-0554-6. - DOI - PubMed
    1. Filip R, Possemiers S, Heyerick A, Pinheiro I, Raszewski G, Davicco MJ, Coxam V. Twelve-month consumption of a polyphenol extract from olive (Olea europaea) in a double blind, randomized trial increases serum total osteocalcin levels and improves serum lipid profiles in postmenopausal women with osteopenia. J Nutr Health Aging. 2015;19:77–86. doi: 10.1007/s12603-014-0480-x. - DOI - PubMed